Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes

Japanese Journal of Clinical Oncology

Volumn 45, Issue 9, 2015, Pages 867-873

  Ichioka, Daishi ^a   Miyazaki, Jun ^a   Inoue, Takamitsu ^b   Kageyama, Susumu ^c   Sugimoto, Mikio ^d   Mitsuzuka, Koji ^e   Matsui, Yoshiyuki ^f   Shiraishi, Yusuke ^g   Kinoshita, Hidefumi ^h   Wakeda, Hironobu ⁱ   Nomoto, Takeshi ^j   Kikuchi, Eiji ^k   Nishiyama, Hiroyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

^h KANSAI MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF MIYAZAKI   (Japan)

^j TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chemotherapy; Cisplatin; EGFR; Gemcitabine; Renal function; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; NEDAPLATIN; VINBLASTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE (PEOPLE); KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84942328455     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv082     Document Type: Article

References (17)

1. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139:461-9.
2. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
3. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506-13.
4. Launay-Vacher V, Ayllon J, Janus N, et al. Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer 2009;7:E83-9.
5. Vaughn DJ. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium. Cancer Treat Rev 2008;34:328-38.
6. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004;91:844-9.
7. Morales-Barrera R, Bellmunt J, Suarez C, et al. Cisplatin and gemcitabine administered every twoweeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer 2012;48:1816-21.
8. Carles J, Nogue M, Domenech M, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000;59:24-7.
9. Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 2001;37:2212-5.
10. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003;97:2180-6.
11. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004;64: 479-84.
12. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52:134-41.
13. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191-9.
14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
15. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
16. Canter D, Viterbo R, Kutikov A, et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011;77: 160-5.
17. Tsao CK, Moshier E, Seng SM, et al. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer 2012;10: 15-20.